PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors

2025-09-08
(Press-News.org) Barcelona, Spain (September 8, 2025, Noon CEST / UTC +2  ) — BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with MTAP-deleted non-small cell lung cancer (NSCLC), according to results from the Phase 1CA240-0007 trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

MTAP, encoding the enzyme methylthioadenosine phosphorylase, is deficient in many cancers. MTA is a byproduct of cellular metabolism that builds up in cancer cells with a specific deletion: the MTAP gene. When MTAP is deleted (MTAP-deleted cancers), MTA accumulates and binds to PRMT5, an enzyme that plays a role in cell regulation and survival. BMS-986504 is designed to selectively target and inhibit PRMT5 when it's bound to MTA (PRMT5-MTA complex), leading to cell death in MTAP-deleted cancer cells.

The study enrolled patients with advanced solid tumors harboring homozygous MTAP deletions, a genetic alteration that occurs in 10-15% of all cancers and NSCLC represents up to 27% of patients with MTAP-del. Among clinically evaluable patients in the NSCLC cohort (n=35), BMS-986504 demonstrated a 29% overall response rate (ORR) and a 80% disease control rate. Two additional patients had unconfirmed responses and were awaiting confirmatory scans. Responses included patients with EGFR and ALK alterations who had progressed on prior TKIs.

“BMS-986504 selectively targets the PRMT5-MTA complex in MTAP-deleted cells while sparing normal tissue, providing a precision approach for a difficult-to-treat patient population,” said Dr. Pasi Jänne of Dana-Farber Cancer Institute, who presented the findings. “These results support continued development of this agent.”

Dr. Jänne reported some additional key findings:

Responses were seen in 4/7 EGFR-positive, 2/4 ALK-positive, and 1/3 squamous patients. Median duration of response: 10.5 months; time to response: 4.3 months. Median follow-up: 11.7 months (95% CI, 4.2–12.4). Dr. Jänne said that BMS-986504 was well tolerated, with most treatment-related adverse events (TRAEs) being grade 1 or 2.  14% of solid tumor patients experienced grade ≥3 TRAEs. Hematologic toxicity rates were low and manageable with patients experiencing treatment-related anemia (8%), neutropenia (7%), and thrombocytopenia (7%).

The study included solid tumor patients with the majority of patients with NSCLC, mesothelioma, pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma. According to Dr. Jänne, no new safety signals were observed across tumor types.

These results support further investigation of BMS-986504 and there are 2 studies for patients with advanced NSCLC with MTAP-del:

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies - NCT06855771 A Randomized Phase 2/3 Study of BMS-986504 in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion - NCT07063745 About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

END


ELSE PRESS RELEASES FROM THIS DATE:

Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) ) — A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). In hypofractionated ...

Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Despite half of lung cancers being diagnosed in people aged 75 or older, randomized evidence on screening outcomes in this age group is limited. Most national lung cancer screening programs, including the UK’s, stop at age 74. The U.S. Preventive ...

Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Video-assisted thoracoscopic surgery (VATS) is currently the most common approach to perform pulmonary lobectomy in early-stage lung cancer. Advantages include reduced pain, fewer complications, faster recovery and improved quality-of-life. The adoption of VATS lobectomy ...

NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile. Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a leading cause of cancer-related ...

EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC

2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2)  — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Consolidation durvalumab improves survival ...

Training to improve memory

2025-09-08
  In Europe, almost one in 10 people over 70 suffers from dementia, and this figure could even triple by 2050 due to rising life expectancy. Over time, those affected lose everything that makes them who they are, including their memory and their ability to go about their everyday lives. Many also suffer from physical deterioration. In an advanced stage of the disorder, dementia patients generally require comprehensive care. Now, the first drugs have emerged that can slightly slow down disease progression in the early stages of Alzheimer’s – ...

Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?

2025-09-08
New research indicates that many patients who undergo surgery with the intent to cure early-stage cancer continue or start opioid prescriptions in the year following surgery. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. Pain management is essential during cancer care, but prescription opioid practices associated with cancer treatment may lead to unsafe long-term opioid use and adverse outcomes such as opioid use disorder and opioid overdose. To assess the ...

Black youth, especially Black girls, use mental health services less than their White peers

2025-09-08
Black adolescents with mental distress are less likely to use mental health services than their White peers, and Black girls are the least likely to access care, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241733. “Adolescence is a crucial developmental stage and a critical period for onset of mental health problems,” writes Mercedes Sobers, a PhD candidate in epidemiology at the Dalla Lana School of Public Health, University of Toronto and research coordinator at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, ...

Canada must protect youth from sports betting advertising

2025-09-08
Canada must enact strong, effective legislation to protect youth from gambling advertising. Minors are suffering harms from problem gambling despite age restrictions, argue authors in an editorial in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251227 . Since 2021, ads for sports betting have saturated sports broadcasts, constantly viewed by children. Gambling is normalized as a natural part of spectatorship at a young age. Even before single-game sports betting was legalized, a 2019 survey of Canadian students in grades 7–12 found about 4% of students ...

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

2025-09-07
First-in-Human Trial Shows Promising Results for DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer (Barcelona, Spain Sunday, September 7, 2025 at 4:45 PM CEST / UTC +2) — A first-in-human Phase 1 study of SHR-4849 (IDE849), a Delta-like ligand 3 (DLL3)-directed antibody-drug conjugate (ADC), demonstrated manageable safety and early signs of anti-tumor activity in patients with relapsed small cell lung cancer (SCLC).  The results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). According to the International Agency for Research on Cancer, ...

LAST 30 PRESS RELEASES:

Hiring in high-growth firms: new study explores the timing of organizational changes

Boosting work engagement through a simple smartphone diary

Climate change may create ‘ecological trap’ for species who can’t adapt

Scientists create ChatGPT-like AI model for neuroscience to build one of the most detailed mouse brain maps to date

AI and omics unlock personalized drugs and RNA therapies for heart disease

2023 ocean heatwave ‘unprecedented but not unexpected’

Johns Hopkins researchers develop AI to predict risk of US car crashes

New drug combination offers hope for men with advanced prostate cancer

New discovery finds gene converts insulin-producing cells into blood-sugar boosters

Powerful and precise multi-color lasers now fit on a single chip

Scientists agree chemicals can affect behavior, but industry workers more reluctant about safety testing

DNA nanospring measures cellular motor power

Elsevier Foundation and RIKEN launch “Envisioning Futures” report: paving the way for gender equity and women’s leadership in Japanese research

Researchers discover enlarged areas of the spinal cord in fish, previously found only in four-limbed vertebrates

Bipolar disorder heterogeneity decoded: transforming global psychiatric treatment approaches

Catching Alport syndrome through universal age-3 urine screening

Instructions help you remember something better than emotions or a good night’s sleep

Solar energy is now the world’s cheapest source of power, a Surrey study finds

Scientists reverse Alzheimer’s in mice using nanoparticles

‘Good’ gut bacteria boosts placenta for healthier pregnancy

USC team demonstrates first optical device based on “optical thermodynamics”

Microplastics found to change gut microbiome in first human-sample study

Artificially sweetened and sugary drinks are both associated with an increased risk of liver disease, study finds

Plastic in the soil, but not as we know it: Biodegradable microplastics rewire carbon storage in farm fields

Yeast proteins reveal the secrets of drought resistance

Psychiatry, primary care, and OB/GYN subspecialties hit hardest by physician attrition

New Canadian study reveals where HIV hides in different parts of the body

Lidocaine poisonings rise despite overall drop in local anesthetic toxicity

Politics follow you on the road

Scientists blaze new path to fighting viral diseases

[Press-News.org] BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors